Detalhe da pesquisa
1.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 389(24): 2256-2266, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870955
2.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 385(13): 1196-1206, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551229
3.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460017
4.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534646
5.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Lancet Oncol
; 20(8): 1083-1097, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221619
6.
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol
; 19(4): 510-520, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29477665
7.
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(7): 916-929, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908991
8.
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
Br J Cancer
; 118(6): 777-784, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438370
9.
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(4): 435-445, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28284557
10.
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
N Engl J Med
; 371(20): 1867-76, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25265494
11.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 17(9): 1248-60, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27480103
12.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med
; 367(2): 107-14, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22663011
13.
Who benefits most from adjuvant interferon treatment for melanoma?
Am J Ther
; 22(1): 54-60, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-24176884
14.
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries.
Am J Ther
; 22(1): 37-43, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-24914500
15.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 380(9839): 358-65, 2012 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22735384
16.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
J Clin Oncol
; 41(3): 528-540, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998300
17.
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
Eur J Cancer
; 163: 79-87, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35042070
18.
Pinpointing the tumor-specific T cells via TCR clusters.
Elife
; 112022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35377314
19.
Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.
Scand J Urol Nephrol
; 45(3): 190-5, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21329481
20.
Screening for Melanoma and Other Skin Cancer Shows a Higher Early Melanoma Incidence: Social Educational Program "Life Fear-Free".
Dermatopathology (Basel)
; 8(1): 54-68, 2021 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33803969